ScholarLens Back to search
2003•Chinese Journal of New Drugs and Clinical RemediesRequires access

Gatifloxacin in treating lower respiratory tract infections

Zhang Li

Open publisher page 0 citations

Abstract

AIM:To evaluate the clinical efficacy and safty of gatifloxacin in the treatment of lower respiratory tract infections. METHODS: Sixty six patients were divided into two groups; Thirty four patients (M 19, F 15; age (35± s 11) a, 18 65 a) were treated with gatifloxacin, 0.4 g, iv, gtt, qd, for 7 14 d, and another thirty two patients (M 18, F 14; age (38±12) a, 18 64 a) were treated with levofloxacin, 0.2 g, iv, gtt, bid, for 7 14 d. RESULTS: The total effective rates of gatifloxacin group and levofloxacin group were 91 % and 91 %, the bacterial clearance rates were 90 % and 90 %, adverse reactions occured in 6 % and 6 %, respectively. CONCLUSION:Gatifloxacin is a safe and potent antibacterial agent in the treatment of the lower respiratory tract infections.

About this research paper

What this paper is about

AIM:To evaluate the clinical efficacy and safty of gatifloxacin in the treatment of lower respiratory tract infections. METHODS: Sixty six patients were divided into two groups; Thirty four patients (M 19, F 15; age (35± s 11) a, 18 65 a) were treated with gatifloxacin, 0.4 g, iv, gtt, qd, for 7 14 d, and another thirty two patients (M 18, F 14; age (38±12) a, 18 64 a) were treated with levofloxacin, 0.2 g, iv, gtt, bid, for 7 14 d. RESULTS: The total effective rates of gatifloxacin group and levofloxacin group were 91 % and 91 %, the bacterial clearance rates were 90 % and 90 %, adverse reactions occured in 6 % and 6 %, respectively. CONCLUSION:Gatifloxacin is a safe and potent antibacterial agent in the treatment of the lower respiratory tract infections.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIM:To evaluate the clinical efficacy and safty of gatifloxacin in the treatment of lower respiratory tract infections. METHODS: Sixty six patients were divided into two groups; Thirty four patients (M 19, F 15; age (35± s 11) a, 18 65 a) were treated with gatifloxacin, 0.4 g, iv, gtt, qd, for 7 14 d, and another thirty two patients (M 18, F 14; age (38±12) a, 18 64 a) were treated with levofloxacin, 0.2 g, iv, gtt, bid, for 7 14 d. RESULTS: The total effective rates of gatifloxacin group and levofloxacin group were 91 % and 91 %, the bacterial clearance rates were 90 % and 90 %, adverse reactions occured in 6 % and 6 %, respectively. CONCLUSION:Gatifloxacin is a safe and potent antibacterial agent in the treatment of the lower respiratory tract infections.

Key concepts: Gatifloxacin, Levofloxacin, Medicine, Respiratory tract infections, Adverse effect, Internal medicine, Respiratory tract, Gastroenterology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Gatifloxacin in treating lower respiratory tract infections — Research Paper | ScholarLens